Galapagos and BASF Extend Research Collaborations
News Feb 02, 2006
These extensions will further progress discovery research services for BASF programmes undertaken by Galapagos' service division BioFocus in 2005.
Across the various programmes, BioFocus will offer biology, synthetic and computational chemistry services, plus access to its biologically-targeted SoftFocus® Kinase and GPCR compound libraries against further BASF targets.
Under the terms of the extension agreements, BASF will pay compound supply and access fees and will fund research activities. Total contract value of the extensions announced today will exceed € 700,000.
"We are delighted that BASF has chosen to extend these collaborations with BioFocus," said Onno van de Stolpe, CEO of Galapagos.
"We believe that our expertise in the area of kinase and GPCR biology and chemistry, together with our proprietary compound libraries, place BioFocus in an excellent position to progress BASF's discovery programmes rapidly."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE